The main indication of prophylactic mastectomy pertains to BRCA1 or BRCA2 mutation carriers. Prophylactic mastectomy includes the simple method and the subcutaneous method. Both methods can be followed by breast plastic reconstruction either at the same time or later. This review examines key issues regarding prophylactic mastectomy: the selection of patients, its effectiveness, its limitations, convergence/divergence in existing guidelines, and future perspectives.
References
1.
RodriquezE.DomchekS.M.The prevention of hereditary breast cancer.Semin Oncol2007; 34: 401–5.
2.
IsernA.E.TengrupI.LomanN.Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction.J Plast Reconstr Aesthet Surg2008; 61: 1177–87.
3.
WeitzelJ.N.McCaffreyS.M.NedelcuR.Effect on genetic cancer risk assessment on surgical decisions at breast cancer diagnosis.Arch Surg2003; 138: 1323–8.
4.
American Society of Clinical Oncology.American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.J Clin Oncol2003; 21: 2397–406.
5.
American Society of Clinical Oncology.Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.J Clin Oncol1996; 14: 1730–6; discussion 1737–40.
6.
RayJ.A.LoescherL.J.BrewerM.Risk-reduction surgery decisions in high-risk women seen for genetic counseling.J Genet Couns2005; 14: 473–84.
7.
TuttleT.M.HabermannE.B.GrundE.H.Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.J Clin Oncol2007; 25: 5203–9.
8.
Barnes-KedarI.M.PlonS.E.Counseling the at risk patient in the BRCA1 and BRCA2 era.Obstet Gynecol Clin North Am2002; 29: 341–66.
9.
NCCN.Guidelines for detection, prevention and risk reduction of cancer. Genetics/familial high risk assessment. National Comprehensive Cancer Network. Available at: www.nccn.com. Accessed Februray 12, 2012.
10.
MetcalfeK.A.GoelV.LickleyL.Prophylactic bilateral mastectomy: patterns of practice.Cancer2002; 95: 236–42.
11.
ClausE.B.SchildkrautJ.M.ThompsonW.D.RischN.J.The genetic attributable risk of breast and ovarian cancer.Cancer1996; 77: 2318–24.
12.
FordD.EastonD.F.StrattonM.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.Am J Hum Genet1998; 62: 676–89.
13.
StruewingJ.P.HartgeP.WacholderS.The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.N Engl J Med1997; 336: 1401–8.
14.
The Breast Cancer Linkage Consortium.Cancer risks in BRCA2 mutation carriers.J Natl Cancer Inst1999; 91: 1310–6.
15.
WestC.N.GeigerA.M.GreeneS.M.Race and ethnicity: comparing medical records to self-reports.J Natl Cancer Inst Monogr2005; 35: 72–4.
16.
LuxM.P.FaschingP.A.BeckmannM.W.Hereditary breast and ovarian cancer: review and future perspectives.J Mol Med2006; 84: 16–28.
17.
KasprzakL.MesurolleB.TremblayF.Invasive breast cancer following bilateral subcutaneous mastectomy in a BRCA2 mutation carrier: a case report and review of the literature.World J Surg Oncol2005; 3: 52.
18.
CasilliF.TournierI.SinilnikovaO.M.The contribution of germline rearrangements to the spectrum of BRCA2 mutations.J Med Genet2006; 43: e49.
19.
WalshT.CasadeiS.CoatsK.H.Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.JAMA2006; 295: 1379–88.
20.
WoodwardA.M.DavisT.A.SilvaA.G.Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.J Med Genet2005; 42: e31.
21.
CasilliF.Di RoccoZ.C.GadS.Rapid detection of novel BRCA1 rearrangements in high-risk breast–ovarian cancer families using multiple PCR of short fluorescent fragments.Hum Mutat2002; 20: 218–26.
22.
Menke-PluymersM.B.SeynaeveC.van GeelA.N.[Preventive surgical procedures for inherited risk of breast cancer] [in Dutch].Ned Tijdschr Geneeskd2005; 149: 2663–7.
23.
OsinP.CrookT.PowlesT.Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.Lancet1998; 351: 1487.
24.
NarodS.A.BrunetJ.S.GhadirianP.Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study.Lancet2000; 356: 1876–81.
25.
ArmesJ.E.TruteL.WhiteD.Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.Cancer Res1999; 59: 2011–7.
ZografosG.C.PanouM.PanouN.Common risk factors of breast and ovarian cancer: recent view.Int J Gynecol Cancer2004; 14: 721–40.
28.
U.S. Preventive Services Task Force.Screening for breast cancer: recommendations and rationale.Ann Intern Med2002; 137: 344–6.
29.
American Academy of Family Physicians.Age Charts for Periodic Health Examinations: Summary of AAFP Policy Recommendations.2002. Available at: www.aafp.org/exam.xml. Accessed June 18, 2002.
30.
GotzcheP.C.OlsenO.Is screening for breast cancer with mammography justifiable?Lancet2000; 355: 129–34.
31.
MayD.S.LeeN.C.NadelM.R.The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medially underserved women.AJR Am J Roentgenol1998; 170: 97–104.
32.
RingashJ.Preventive health care, 2001 update: screening mammography among women aged 40–49 years at average risk of breast cancer.CMAJ2001; 164: 469–76.
33.
Calderon-MargalitR.PaltielO.Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.Int J Cancer2004; 112: 357–64.
34.
AdemC.JenkinsR.B.CapronF.Stoppa-LyonnetD.High-risk lesions in high-risk women: a high-risk formalin-based biology!J Clin Oncol2004; 22: 1159–61.
35.
SmithK.L.AdankM.KauffN.BRCA mutations in women with ductal carcinoma in situ.Clin Cancer Res2007; 13: 4306–10.
36.
RemmelE.HarderF.Prophylactic mastectomy—evaluation and treatment of high risk patients.Swiss Surg2002; 8: 45–52.
37.
HorsmanD.WilsonB.J.AvardD.Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.J Obstet Gynaecol Can2007; 29: 45–60.
38.
EisingerF.BressacB.CastaigneD.Identification and management of hereditary breast–ovarian cancers (2004 update).Pathol Biol (Paris)2006; 54: 230–50.
39.
WainbergS.HustedJ.Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.Cancer Epidemiol Biomarkers Prev2004; 13: 1989–95.
40.
BotkinJ.R.SmithK.R.CroyleR.T.Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.Am J Med Genet2003; 118A: 201–9.
41.
LermanC.HughesC.CroyleR.T.Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.Prev Med2000; 31: 75–80.
42.
LodderL.N.FretsP.G.TrijsburgR.W.One-year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).Breast Cancer Res Treat2002; 73: 97–112.
43.
Meijers-HeijboerE.J.VerhoogL.C.BrekelmansC.T.M.Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.Lancet2000; 335: 2015–20.
44.
ScheuerL.KauffN.RobsonM.Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.J Clin Oncol2002; 25: 1260–8.
45.
GronwaldJ.ByrskiT.HuzarskiT.A survey of preventive measures among BRCA1 mutation carriers from Poland.Clin Genet2007; 71: 153–7.
46.
UyeiA.PetersonS.K.ErlichmanJ.Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.Cancer2006; 107: 2745–51.
47.
GravesK.D.PeshkinB.N.HalbertC.H.Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.Breast Cancer Res Treat2007; 104: 321–9.
48.
BriasoulisE.RoukosD.H.Contralateral prophylactic mastectomy: mind the genetics.J Clin Oncol2008; 26: 1909–10; author reply 1910.
49.
SilvaE.Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist.Fam Cancer2008; 7: 91–5.
50.
FatourosM.BaltoyiannisG.RoukosD.H.The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.Ann Surg Oncol2008; 15: 21–33.
51.
FrostM.H.SlezakJ.M.TranN.V.Satisfaction after contralateral prophylactic mastectomy, and body appearance.J Clin Oncol2005; 23: 7849–56.
52.
GloshK.HartmannL.C.Current status of prophylactic mastectomy.Oncology (Hyntingt)2002; 16: 1319–25, discussion 1325, 1329–30, 1332.
53.
WijayanayagamA.KumarA.S.FosterR.D.EssermanL.J.Optimizing the total skin-sparing mastectomy.Arch Surg2008; 143: 38–45.
54.
BresserP.J.SeynaeveC.Van GoolA.R.Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.Plast Reconstr Surg2006; 117: 1675–82.
55.
BartonM.B.WestC.N.LiuI.L.Complications following bilateral prophylactic mastectomy.J Natl Cancer Inst Monogr2005; 35: 61–6.
56.
MacLennanS.E.Bilateral breast reconstruction and the role of prophylactic mastectomy.Breast Dis2002; 16: 23–9.
57.
BlackD.SpechtM.LeeJ.M.Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy.Ann Surg Oncol2007; 14: 2477–84.
58.
BougheyJ.C.CormierJ.N.XingY.Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy.Cancer2007; 2007: 2542–50.
59.
SoranA.FalkJ.BonaventuraM.Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience.Ann Surg Oncol2007; 14: 646–51.
60.
RebbeckT.R.FriebelT.LynchH.T.Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.J Clin Oncol2004; 22: 1055–62.
61.
Meijers-HeijboerH.van GeelB.van PuttenW.L.Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation.N Engl J Med2001; 345: 159–64.
62.
HartmannL.C.SellersT.A.SchaidD.J.Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.J Natl Cancer Inst2001; 93: 1633–7.
63.
MetcalfeK.A.NarodS.A.Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.J Natl Cancer Inst2002; 94: 1564–9.
64.
Heemskerk-GerritsenB.A.BrekelmansC.T.Menke-PluymersM.B.Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.Ann Surg Oncol2007; 14: 3335–44.
65.
Van SprundelT.C.SchmidtM.K.RookusM.A.Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.Br J Cancer2005; 93: 287–92.
66.
HerrintonL.J.BarlowW.E.YuO.Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project.J Clin Oncol2005; 23: 4275–86.
67.
EastonD.F.FordD.BishopD.T.Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium.Am J Hum Genet1995; 56: 265–71.
68.
RebbeckT.R.LevinA.M.EisenA.Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.J Natl Cancer Inst1999; 91: 1475–9.
69.
SchmelerK.M.SunC.C.BodurkaD.C.Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.Obstet Gynecol2006; 108: 515–20.
70.
GrannV.R.JacobsonJ.S.WhangW.Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.Cancer J Sci Am2000; 6: 13–20.
71.
GoldflamK.HuntK.K.GershenwaldJ.E.Contralateral prophylactic mastectomy. Predictors of significant histologic findings.Cancer2004; 101: 1977–86.
72.
BartonM.B.WestC.N.LiuI.L.Complications following bilateral prophylactic mastectomy.J Natl Cancer Inst Monogr2005; 35: 61–6.
73.
Von SmittenK.Prophylactic mastectomy: why and when?J Br Menopause Soc2003; 9: 151–5.
74.
GahmJ.JurellG.WickmanM.HanssonP.Sensitivity after bilateral prophylactic mastectomy and immediate reconstruction.Scand J Plast Reconstr Surg Hand Surg2007; 41: 178–83.
75.
FullerS.AndersonR.C.Adjustment issues related to bilateral prophylactic mastectomy in women at elevated risk of developing breast cancer.Plast Surg Nurs2006; 26: 60–5.
76.
FrostM.H.SchaidD.J.SellersT.A.Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy.JAMA2000; 284: 319–24.
77.
ZionS.M.SlezakJ.M.SellersT.A.Reoperations after prophylactic mastectomy with or without implant reconstruction.Cancer2003; 98: 2152–60.
78.
RolnickS.J.AltschulerA.NekhlyudovL.What women wish they knew before prophylactic mastectomy.Cancer Nurs2007; 30: 285–91.
79.
BresserP.J.Van GoolA.R.SeynaeveC.Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?Ann Oncol2007; 18: 1641–5.
80.
McGaugheyA.Body image after bilateral prophylactic mastectomy: an integrative literature review.J Midwifery Womens Health2006; 51: e45–9.
GravesK.D.PeshkinB.N.HalbertC.H.Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.Breast Cancer Res Treat2007; 104: 321–9.
83.
StolierA.J.CorsettiR.L.Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.Am Surg2005; 71: 1031–3.
84.
GeigerA.M.NekhlyudovL.HerrintonL.J.Quality of life after bilateral prophylactic mastectomy.Ann Surg Oncol2007; 14: 686–94.
85.
PressN.ReynoldsS.PinskyL.That's like chopping off a finger because you're afraid it might get broken: disease and illness in women's views of prophylactic mastectomy.Soc Sci Med2005; 61: 1106–17.
86.
AckermannS.LuxM.P.FaschingP.A.Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers.Eur J Cancer Prev2006; 15: 474–9.
87.
VodermaierA.BauerfeindI.UntchM.Nestle-KramlingC.Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation.Psychother Psychosom Med Psychol2006; 56: 351–61.
88.
EisingerF.Prophylactic mastectomy: ethical issues.Br Med Bull2007; 81-82: 7–19.
89.
McDonnellS.K.SchaidD.J.MyersJ.L.Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.J Clin Oncol2001; 19: 3938–43.
90.
DupontW.D.PageD.L.Risk factors for breast cancer in women with proliferative breast disease.N Engl J Med1985; 312: 146–51.
91.
FidzgibbonsP.L.HensonD.E.HutterR.V.Bening breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists.Arch Pathol Lab Med1998; 122: 1053–5.
92.
KerlikowwskeK.GradyD.BarklayJ.Positive predictive value of screening mammography by age and family history of breast cancer.JAMA1993; 270: 2444–50.
93.
KerlikowskeK.CarneyP.A.GellerB.Performance of screening mammography among women with and without a first degree relative with breast cancer.Ann Intern Med2000; 133: 855–63.
94.
MetcalfeK.A.Prophylactic bilateral mastectomy for breast cancer prevention.J Womens Health (Larchmt)2004; 13: 822–9.
95.
HermsenB.B.VerheijenR.H.MenkoF.H.Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.Eur J Cancer2007; 43: 1556–63.
96.
Von SmittenK.Prophylactic mastectomy: why and when?J Br Menopause Soc2003; 9: 151–5.
97.
BaoT.ProwellT.StearnsV.Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.Am J Ther2006; 13: 337–48.
98.
HughesK.S.PapaM.Z.WhitneyT.McLellanR.Prophylactic mastectomy and inherited predisposition to breast carcinoma.Cancer1999; 86: 2502–16.
99.
LermanC.HughesC.CroyleR.T.Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.Prev Med2000; 31: 75–80.
100.
Meijers-HeijboerE.J.VerhoogL.C.BrekelmansC.T.Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 and BRCA2 mutation.Lancet2000; 355: 2015–20.
101.
ScottC.I.IorgulescuD.G.ThorneH.J.Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.Clin Genet2003; 64: 111–21.
102.
Menke-PluymersM.B.SeynaeveC.van GeelA.N.[Preventive surgical prcedures for inherited risk of breast cancer] [in Dutch].Ned Tijdschr Geneeskd2005; 149: 2663–7.
103.
WickmanM.SandelinK.ArverB.Technical aspects and outcome after prophylactic mastectomy and immediate breast reconstruction in 30 consecutive high-risk patients.Plast Reconstr Surg2003; 111: 1069–77.
